When a new strain of flu virus sickened 1,000 dogs and killed 5 in Chicago back in April, animal health experts wondered just how bad subsequent outbreaks would be. Now more cases are cropping up across the country, setting off red flags from vets and pet owners.
Merck is nearing FDA approval for its Clostridium difficile-fighting antibody, picking up the agency's priority review designation with the promise of a shortened vetting process.
Using a "systems vaccinology" approach, researchers at Case Western Reserve University School of Medicine and Merck Research Laboratories have published findings that suggest a new way to predict and enhance vaccine effectiveness, in particular with hepatitis B vaccination.
Merck's candidate is the furthest along in the quest for an Ebola vaccine, having posted interim Phase III data showing 100% efficacy last July. Now, the Big Pharma has won $5 million from Gavi, the global vaccine alliance, to help see its candidate through late-stage trials, licensure and prequalification by the WHO, and plans to submit the vaccine for regulatory approval by the end of 2017.
Merck has won a legal battle over Merck, which in return says it will file a lawsuit against Merck. It sounds confusing, but confusion is the essence of the legal battle between Germany's Merck KGaA and U.S.-based Merck & Co., known as MSD outside the U.S. The companies are engaged in a dispute largely over the misunderstandings brought about from sharing the same name for nearly 125 years.
Merck is closing a chapter in its seemingly never-ending saga for its painkiller Vioxx, agreeing to pay more than $800 million to settle a lawsuit over the med years after the company pulled its product from the market and shelled out billions to resolve additional suits.
SAN FRANCISCO-- On Monday, we brought you the lowdown from the J.P. Morgan Healthcare Conference, with company presentations from pharma giants including Novartis and Merck & Co. Today, we're back with our latest roundup, big names and not-so-big.
In a move aimed at doubling the world's cholera vaccine supply, the World Health Organization has given its nod to South Korean's EuBiologics to provide vaccines under its prequalification program.
Israeli drug developer BioLineRx is partnering with Merck to see whether its in-development cancer therapy can work in tandem with an approved treatment that taps the power of the immune system, joining a long list of clinical partners.
SAN FRANCISCO-- Look out, Merck & Co.: GlaxoSmithKline expects its shingles candidate, Shingrix, to be a "major market disrupter" when it wins approval.